267 related articles for article (PubMed ID: 10740254)
1. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.
Brown JM
Mol Med Today; 2000 Apr; 6(4):157-62. PubMed ID: 10740254
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment and the response to anticancer therapy.
Brown JM
Cancer Biol Ther; 2002; 1(5):453-8. PubMed ID: 12496469
[TBL] [Abstract][Full Text] [Related]
3. Tumor hypoxia in cancer therapy.
Brown JM
Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
6. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.
Shannon AM; Bouchier-Hayes DJ; Condron CM; Toomey D
Cancer Treat Rev; 2003 Aug; 29(4):297-307. PubMed ID: 12927570
[TBL] [Abstract][Full Text] [Related]
7. Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
Brown JM
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):12-4. PubMed ID: 9647614
[TBL] [Abstract][Full Text] [Related]
8. Tirapazamine: from bench to clinical trials.
Marcu L; Olver I
Curr Clin Pharmacol; 2006 Jan; 1(1):71-9. PubMed ID: 18666379
[TBL] [Abstract][Full Text] [Related]
9. Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells.
Um JH; Kang CD; Bae JH; Shin GG; Kim DW; Kim DW; Chung BS; Kim SH
Exp Mol Med; 2004 Jun; 36(3):233-42. PubMed ID: 15272235
[TBL] [Abstract][Full Text] [Related]
10. How to overcome (and exploit) tumor hypoxia for targeted gene therapy.
Greco O; Marples B; Joiner MC; Scott SD
J Cell Physiol; 2003 Dec; 197(3):312-25. PubMed ID: 14566961
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia inducible factor as a cancer drug target.
Welsh SJ; Powis G
Curr Cancer Drug Targets; 2003 Dec; 3(6):391-405. PubMed ID: 14683498
[TBL] [Abstract][Full Text] [Related]
12. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
13. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA; Wilson WR
Expert Opin Investig Drugs; 2000 Dec; 9(12):2889-901. PubMed ID: 11093359
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
15. Tirapazamine: a novel agent targeting hypoxic tumor cells.
Reddy SB; Williamson SK
Expert Opin Investig Drugs; 2009 Jan; 18(1):77-87. PubMed ID: 19053884
[TBL] [Abstract][Full Text] [Related]
16. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
17. Bioreductive drugs: from concept to clinic.
McKeown SR; Cowen RL; Williams KJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):427-42. PubMed ID: 17482438
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway.
Nagasawa H; Mikamo N; Nakajima Y; Matsumoto H; Uto Y; Hori H
Anticancer Res; 2003; 23(6a):4427-34. PubMed ID: 14666730
[TBL] [Abstract][Full Text] [Related]
20. The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.
Shibamoto Y; Sugie C; Ito M; Ogino H
Expert Opin Pharmacother; 2004 Dec; 5(12):2459-67. PubMed ID: 15571464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]